CompanyHealthAi
Fore Biotherapeutics
Fore Biotherapeutics is a Philadelphia-based, registration-stage precision oncology company developing targeted therapies for patients with hard-to-treat cancers. Its lead candidate, plixorafenib, is a next-generation BRAF inhibitor (a 'dimer breaker') aimed at BRAF-altered solid tumors, including BRAF V600E-mutated high-grade glioma, for which it received FDA Breakthrough Therapy Designation in 2026. Spun out of the Israeli functional-genomics company NovellusDx, Fore has raised more than $200M to push plixorafenib toward an accelerated FDA approval pathway.
2011Founded
PhiladelphiaHQ
~$91.5M cumulative priorEarlier rounds (incl. NovellusDx era)
precision oncologybiotechnologybraf inhibitorplixorafenibcancertargeted therapy